Literature DB >> 1714231

Antineutrophil cytoplasmic autoantibodies antigen specificity.

P Lesavre1.   

Abstract

The results presented during the Third International ANCA Workshop, Washington, DC, 1990, allowed a better definition of the antigenic specificity of the antineutrophil cytoplasmic autoantibodies (ANCA). The large predominance of two major antigen specificities for proteinase 3 (PR3) and myeloperoxidase (MPO), in the group of vasculitic patients, was confirmed. PR3 and MPO are colocalized in the azurophilic granules of neutrophils and translocated to the cell surface during activation and thus are able to interact with ANCA after neutrophil preactivation. Furthermore, by comparison of amino acid and DNA sequences, the agreement was reached that PR3 was identical to AGP7, p29, and myeloblastin, described independently and involved in the control of growth and differentiation of leukemic cells. In addition to the two major ANCA antigens, a number of neutrophil cytoplasmic antigens recognized by ANCA have been previously identified (human leukocyte elastase [HLE], lactoferrin). It was established during the Third Workshop that these rare ANCA specificities, occurring in a limited number of patients, include a cationic antimicrobial protein (CAP57) and cathepsin G. However, the variety of ANCA antigen specificities contrasts with the fact that the vast majority of ANCA-positive sera are monospecific for a single ANCA antigen. Finally, the fine specificity of granulocyte-specific antinuclear antibodies (GS-ANA) occurring in rheumatoid arthritis and ulcerative colitis is still unknown, but clearly a substantial proportion of GS-ANA belongs to the ANCA family.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714231     DOI: 10.1016/s0272-6386(12)80873-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  16 in total

Review 1.  The antigenic significance and methods of detection of the anti-neutrophil cytoplasmic autoantibodies (ANCA).

Authors:  X Bosch; R A Asherson
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

2.  Sustained monocyte activation in clinical remission of systemic vasculitis.

Authors:  Agneta Wikman; Joachim Lundahl; Stefan H Jacobson
Journal:  Inflammation       Date:  2008-12       Impact factor: 4.092

3.  Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations.

Authors:  Irena Manolova; Maria Dantcheva
Journal:  Rheumatol Int       Date:  2004-11-11       Impact factor: 2.631

4.  Immunoglobulin subclass determines ability of immunoglobulin (Ig)G to capture and activate neutrophils presented as normal human IgG or disease-associated anti-neutrophil cytoplasm antibody (ANCA)-IgG.

Authors:  T Pankhurst; G Nash; J Williams; R Colman; A Hussain; C Savage
Journal:  Clin Exp Immunol       Date:  2011-03-10       Impact factor: 4.330

5.  Clinical relevance of testing for antineutrophil cytoplasm antibodies (ANCA) with a standard indirect immunofluorescence ANCA test in patients with upper or lower respiratory tract symptoms.

Authors:  A Davenport; R J Lock; T B Wallington
Journal:  Thorax       Date:  1994-03       Impact factor: 9.139

Review 6.  ACP Broadsheet No 143: January 1994. Detection of autoantibodies to neutrophil cytoplasmic antigens.

Authors:  R J Lock
Journal:  J Clin Pathol       Date:  1994-01       Impact factor: 3.411

7.  Cardiac involvement in Wegener's granulomatosis.

Authors:  N E Goodfield; S Bhandari; W D Plant; A Morley-Davies; G R Sutherland
Journal:  Br Heart J       Date:  1995-02

8.  Antineutrophil cytoplasmic antibodies in Wegener's granulomatosis.

Authors:  S N Wong; V Shah; M J Dillon
Journal:  Arch Dis Child       Date:  1998-09       Impact factor: 3.791

9.  Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis.

Authors:  L Halbwachs-Mecarelli; P Nusbaum; L H Noël; D Reumaux; S Erlinger; J P Grünfeld; P Lesavre
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

10.  Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass.

Authors:  G Cambridge; M Williams; B Leaker; M Corbett; C R Smith
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.